| Date | Title | Description |
| 01.09.2026 | Cherubic Ventures Closes $68.88 Million Fund VI as AUM Surpasses $500 Million | Early Investment Sudo AI Valued at Nearly $2B
TAIPEI, Sept. 1, 2026 /PRNewswire/ -- Cherubic Ventures today announced the close of its sixth fund (Fund VI) at $68.88 million. The fund size reflects the auspicious meaning of the number eight... |
| 24.08.2026 | Stocks making the biggest moves midday: Expedia, Nvidia, Strategy, Hims & Hers and more | - |
| 19.08.2026 | Companies with huge datasets can save up to 80% in AI costs by using open-weight models: Hims CEO | One executive is touting open-weight models, especially if your company produces lots of data.
In an interview with CNBC Squawkbox, released on Tuesday, Hims & Hers CEO Andrew Dudum said companies that already have large datasets should... |
| 18.08.2026 | Hims & Hers CEO says FTC lawsuit misunderstands how the company works | Hims & Hers CEO Andrew Dudum defended the company against against an FTC lawsuit over its data sharing and subscription practices.
In an interview with CNBC, he also said the company’s sale of compounded GLP-1 drugs helped to bring pric... |
| 12.08.2026 | Utah Sues Hims & Hers | SALT LAKE CITY, UT—The Utah Department of Commerce’s Division of Consumer Protection and the Office of the Utah Attorney General have joined the Federal Trade Commission (FTC) and the State of California in a federal lawsuit against telehea... |
| 11.08.2026 | Stocks making the biggest moves premarket: Riot Platforms, Hims & Hers Health, Intel & more | - |
| 10.08.2026 | Hims & Hers Q2 2026 Earnings: $86M GAAP Loss Despite $753M Revenue Beat | By Joshua Mitchell
Published: Aug 10 2026, 5:21 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 30.07.2026 | Markets Roil: AI Tech Falters, Oil Swings, Fed Holds Firm Amid Global Tensions | Markets reel from deep AI stock sell-offs this week. Major indexes saw mixed results, with oil prices volatile due to Mideast conflict. The Federal Reserve maintained interest rates, fueling market uncertainty. Corporations now question AI'... |
| 30.07.2026 | Utah Sues Hims & Hers for Charging Consumers Without Consent and Sharing Their Private Health Data | SALT LAKE CITY—The Utah Department of Commerce’s Division of Consumer Protection and the Office of the Utah Attorney General have joined the Federal Trade Commission (FTC) and the State of California in a federal lawsuit against telehealth ... |
| 30.07.2026 | US FTC sues Hims & Hers for sending user health info to Meta, Snap | July 29 : The U.S. Federal Trade Commission sued Hims & Hers on Wednesday alleging the telehealth platform shared users' health data with online advertisers, despite promising privacy, and engaged in deceptive billing and cancellation p... |
| 29.07.2026 | Oil prices jump, while the Dow drops more than 1,100 as sinking AI stocks drag Wall Street lower | Getting your Trinity Audio player ready...
By STAN CHOE, AP Business Writer
NEW YORK (AP) — Oil prices got back to jumping on Wednesday, while sinking technology stocks dragged Wall Street lower amid uncertainty about what the Federal Reser... |
| 29.07.2026 | Hims and Hers shares fall 10% as FTC sues company over data, billing practices | The FTC alleged Hims and Hers shared sensitive user health information with advertisers including Meta and Snap through tracking technologies without proper consent.
Regulators also accuse the telehealth company of charging customers for pr... |
| 29.07.2026 | FTC Sues Hims and Hers: Telehealth Giant Routed Patient Data to Meta Without Consent | By Joshua Mitchell
Published: Jul 29 2026, 2:18 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 12.07.2026 | US Healthcare Landscape Shifts: Access, Innovation, and Political Fault Lines | US healthcare faces unprecedented shifts. ACA enrollment declines amid federal subsidy cuts. Gender-affirming care shrinks under political pressure. Medicare AI causes patient care delays. Abortion access battles intensify over telehealth a... |
| 11.07.2026 | A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss | Vivani Medical believes a tiny implant placed under the skin could help address the biggest issue with blockbuster GLP-1s: keeping patients on treatment to maintain their weight loss.
The biotech company is in the early stages of developing... |
| 26.06.2026 | Estrogen patches are hard to find, and it may not be resolved any time soon | Estrogen patches are hard to find as demand for menopause support skyrockets.
Hormone replacement therapy has been becoming more popular as women share stories on social media and after the FDA removed a black box warning on the medications... |
| 12.05.2026 | Hims & Hers plummets 13% after first-quarter loss, weak earnings guidance | Digital health firm Hims & Hers’ stock plummeted on Tuesday on weak first-quarter earnings.
Hims reported a net loss of $92 million in the first quarter, up from $50 million last year.
The company recently reached an agreement with Novo... |
| 11.05.2026 | Daily Stock Market Live
S&P 500 retreats from record as tech rally cools off, inflation flares up again: Live updates | The S&P 500 slipped on Tuesday, weighed down by losses in technology stocks and higher oil prices, as traders reacted to a hotter-than-expected annual consumer price index reading for April.
The broad market index was 0.6% lower, and th... |
| 11.05.2026 | Stocks making the biggest moves after hours: Hims & Hers, Gitlab, Cleanspark, Webtoon Entertainment & more | - |
| 03.11.2025 | Stocks making the biggest moves after hours: Palantir, Hims & Hers Health, Clorox and more | - |
| 02.11.2025 | Where the blockbuster weight loss drug market stands today — and what’s coming next | The blockbuster weight loss drug market is entering a new chapter of growth.
Eli Lilly and Novo Nordisk are both focused on fighting for market share, ramping up supply, testing new uses for their medicines and bringing the next wave of obe... |
| 17.10.2025 | Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s | Shares of Eli Lilly and Novo Nordisk dropped Friday, after President Donald Trump said his administration aims to cut the cost of brand name GLP-1 weight loss drugs to $150 per month, a fraction of their current list price.
Centers for Medi... |
| 16.09.2025 | German Startups Secure Major Funding, Drive Tech Consolidation | German startups attract major capital and witness significant consolidation. Munich's Agri-PV innovator feld.energy secures €10 million, led by HV Capital, to expand dual-use solar farming. Neumünster-based encentive lands €6.3 million for ... |
| 16.09.2025 | FDA takes aim at Hims & Hers, weight loss drugs in new advertising blitz | By MATTHEW PERRONE, AP Health Writer
WASHINGTON (AP) — For the first time, federal health officials are taking aim at telehealth companies promoting unofficial versions of prescription drugs — including popular weight loss medications — as ... |
| 16.09.2025 | +++ André Schürrle +++ DRYLL +++ Zava +++ feld.energy +++ Autodoc +++ Heilbronn Slush’D +++ | Was gibt’s Neues? In unserem #StartupTicker liefern wir eine kompakte Übersicht über die wichtigsten Startup-Nachrichten des Tages (Dienstag, 16. September). #STARTUPLAND
SAVE THE DATE: Am 5. November findet unsere zweite STARTUPLAND statt.... |
| 11.09.2025 | Health care inflation rises as patients, employers brace for biggest jump in health spending in 15 years | Medical care costs rose 4.2% in August, according to the Consumer Price Index, now at the highest level in three years.
Large employers are projecting a 9% increase in overall health care spending for 2026, and a 12% increase when it comes ... |
| 09.09.2025 | Trump signs memo to crack down on direct-to-consumer pharma ads | President Donald Trump signed a memorandum that aims to crack down on direct-to-consumer prescription drug ads, in a move that stops short of an outright ban.
The Trump administration will send out around 100 cease-and-desist enforcement le... |
| 04.08.2025 | Hims & Hers stock falls 10% on revenue miss | Hims & Hers Health shares fell in extended trading after the company reported second-quarter results that missed Wall Street’s expectations for revenue.
Revenue increased 73% year over year to $544.8 million.
Hims & Hers reported ad... |
| 04.08.2025 | Stocks making the biggest moves after hours: Palantir, Hims & Hers Health, Vertex Pharmaceuticals and more | - |
| 09.07.2025 | Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses | Hims & Hers Health announced plans to expand to Canada in 2026.
Hims will offer generic copies of semaglutide drugs in Canada as Novo Nordisk loses patent protection.
Novo Nordisk will lose its patent protection on its branded semagluti... |
| 25.06.2025 | The Market Pulse: Navigating Turbulent Waters | The stock market is a fickle beast, swayed by whispers of geopolitical tensions and corporate maneuvers. As investors gear up for another trading day, understanding the landscape is crucial. Recent events have set the stage for a volatile w... |
| 24.06.2025 | 5 Things to Know
5 things to know before the stock market opens Tuesday | Stocks closed higher as investors hope the Iran-U.S. conflict will be contained.
Israel accused Iran of violating a ceasefire that U.S. President Donald Trump laid out.
Novo Nordisk has ended its collaboration with telehealth company Hims &... |
| 23.06.2025 | Novo Nordisk exits obesity-drug partnership with Hims & Hers, cites compounding concerns | - |
| 23.06.2025 | Stocks rally and oil tumbles as Wall Street hopes for a limited retaliation after US strikes on Iran | Perhaps most importantly for financial markets, Iran’s retaliation did not seem to target the flow of oil. The fear throughout the Israel-Iran war has been that it could squeeze the world’s supply of oil, which would pump up prices for it, ... |
| 23.06.2025 | Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 34% | Novo Nordisk said it is ending its collaboration with Hims & Hers due to concerns about the telehealth company’s sales and promotion of cheaper knock-offs of the weight loss drug Wegovy.
Novo Nordisk in April said it would offer Wegovy ... |
| 03.06.2025 | Hims & Hers to acquire European telehealth platform in global expansion | Hims & Hers Health announced Tuesday it will acquire European telehealth platform Zava.
The deal will expand Hims’ services to Ireland, France and Germany and will grow its active customer base by roughly 50%.
The deal is set to close b... |
| 03.06.2025 | Stocks making the biggest moves premarket: Dollar General, Constellation Energy, Pinterest, Hims & Hers Health and more | - |
| 02.06.2025 | European autos stocks fall 2% after Trump’s 50% steel tariffs inflate EU trade tensions | This was CNBC’s live blog covering European financial markets.
European stock markets ended the first trading day of the week lower.
The Stoxx Europe 600 index was down 0.1%, France’s CAC 40 was lower by 0.2%, and Germany’s DAX was off by 0... |
| 26.05.2025 | Kraft Heinz Faces the Heat: A Recipe for Change Amid Sales Decline | Kraft Heinz is at a crossroads. The iconic food giant, known for its ketchup and Lunchables, is feeling the pinch. Sales are slipping, and the company is exploring “strategic transactions” to regain its footing. This move is more than just ... |
| 24.05.2025 | MarketBeat Week in Review – 05/19 - 05/23 Stocks were moving lower to end the week as tariff concerns returned; however NVIDIA earnings next week may help investors climb the wall of worry | Stocks were moving lower to end the week as tariff concerns took center stage heading into the long holiday weekend. Prior to two social media posts from President Trump, the NASDAQ and S&P 500 looked like they might eke out a small gai... |
| 20.05.2025 | Weight-loss company Noom pivots to smaller doses of compounded Wegovy | Weight-loss company Noom pivots to smaller doses of compounded Wegovy
By Amina NiasseMay 20, 202510:03 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Item 1 of 2 Smartphone with Noom logo is se... |
| 07.05.2025 | Hims & Hers: A Rising Star in Telehealth | In the fast-paced world of telehealth, Hims & Hers Health is making waves. Founded in 2017, this direct-to-consumer platform has transformed how people access healthcare. It went public in January 2021, and since then, its stock has bee... |
| 07.05.2025 | Novo Nordisk shares pop as drugmaker sees copycat Wegovy sales easing in 2025 | Shares of Novo Nordisk climbed on Wednesday after it said that sales of its blockbuster Wegovy weight loss drug were seen improving in the second half of the year as copycat compounded drugs are phased out.
The Danish pharmaceutical giant r... |
| 06.05.2025 | Reviving American Pharma: A Bold Move or a Risky Gamble? | In a landscape where the pharmaceutical industry has become a global chessboard, President Donald Trump has made a significant move. He signed an executive order aimed at revitalizing domestic drug manufacturing. This decision comes at a ti... |
| 06.05.2025 | How much a $1,000 investment in Hims & Hers at its IPO would be worth now | Shares of telehealth company Hims & Hers Health got a boost last week on news that it will start offering popular weight-loss drug Wegovy.
Founded in 2017, Hims & Hers is a direct-to-consumer telehealth platform that went public in ... |
| 05.05.2025 | Hims & Hers brings former Amazon executive into C-suite | Hims & Hers Health announced Nader Kabbani will join the telehealth company as its new chief operations officer.
Kabbani spent nearly 20 years at Amazon, where he oversaw the launch of Amazon Pharmacy, the company’s acquisition of PillP... |
| 03.05.2025 | The Cost of Health: GLP-1s and the Future of Employer Healthcare | In the world of healthcare, costs often rise like a tide, relentless and overwhelming. But a new wave is forming, one that promises to reshape the landscape of employer-sponsored health plans. This wave is driven by GLP-1 medications, a cla... |
| 03.05.2025 | Eli Lilly and CVS Health: A Tale of Two Giants in the Pharmaceutical Arena | In the ever-evolving landscape of healthcare, two titans, Eli Lilly and CVS Health, have recently made headlines. Their stories are woven with threads of soaring sales, strategic pivots, and cautious optimism. Both companies navigate the st... |
| 01.05.2025 | CVS tops estimates, hikes guidance as insurance business shows some improvement | CVS Health reported first-quarter revenue and profit that topped estimates and hiked its guidance, as its troubled insurance business showed some improvement during the period.
The company now expects full-year adjusted earnings of $6 to $6... |
| 30.04.2025 | GLP-1s can help employers lower medical costs in 2 years, new study finds | Aon researchers found that within two years, improved health outcomes for patients who were taking GLP-1 drugs lowers the growth rate of medical care costs.
Aon looked at medical claims data for 139,000 U.S.-based workers with employer heal... |
| 29.04.2025 | Stocks making the biggest moves midday: Spotify, Regeneron, Hims & Hers, Pfizer and more | - |
| 29.04.2025 | Stocks making the biggest moves premarket: Spotify, Hims & Hers, Sherwin-Williams and more | - |
| 25.04.2025 | The Ozempic Dilemma: Legal Battles and Drug Shortages | In the world of pharmaceuticals, the stakes are high. A recent U.S. court ruling has sent ripples through the healthcare landscape, particularly affecting diabetes and weight-loss treatments. The case centers on Ozempic and Wegovy, two popu... |
| 25.04.2025 | US Court halts production of Ozempic copies amid shortage in drug supply | April 24 - A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes and weight-loss drugs Ozempic and Wegovy while a legal challenge over drug shortages unfolds, court record... |
| 25.04.2025 | Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic | Novo Nordisk scored a huge legal victory that largely restricts compounding pharmacies from marketing or selling cheaper, unapproved versions of the drugmaker’s blockbuster weight loss drug Wegovy and diabetes treatment Ozempic.
U.S. Distri... |
| 14.04.2025 | Pfizer scraps daily weight loss pill after liver injury in one patient | Pfizer said it would end development of its experimental daily weight loss pill after a patient experienced a liver injury that was potentially caused by the drug in a trial.
The patient’s liver enzymes “recovered rapidly” after they stoppe... |
| 11.04.2025 | ATA Action Launches Virtual Foodcare Coalition to Integrate Nutrition with Virtual Care | Image by freepik
What You Should Know:
– ATA Action, the advocacy arm of the American Telemedicine Association launches its new Virtual Foodcare Coalition.
– The advocacy group is dedicated to promoting policies that integrate virtual care ... |
| 09.04.2025 | The Shifting Landscape of Healthcare: Walgreens and Transcarent Navigate New Waters | The healthcare sector is undergoing a seismic shift. Two major players, Walgreens and Transcarent, are charting their courses through turbulent waters. Walgreens, a stalwart in the retail pharmacy world, is preparing to go private. Meanwhil... |
| 08.04.2025 | Market Update: Trident Digital Tech Holdings, Tesla, Hims & Hers Health, and SoFi Technologies Experience Notable Market Activity | Winter Garden, Florida, April 8th, 2025, FinanceWire
The stock market has recently witnessed significant movements among key players in the technology and healthcare sectors. This release provides an overview of the latest trading activity ... |
| 08.04.2025 | Digital health startup Transcarent takes Accolade private in $621 million deal | Transcarent on Tuesday announced it has completed its $621 million acquisition of Accolade.
Accolade shareholders received $7.03 per share in cash, and the company will no longer be listed on the Nasdaq.
Transcarent CEO Glen Tullman previou... |
| 04.04.2025 | Hims & Hers and Eli Lilly: A New Era in Weight Loss and Genetic Medicine | In the ever-evolving landscape of healthcare, two companies are making waves: Hims & Hers and Eli Lilly. Each is carving out a niche in the burgeoning fields of weight loss and genetic medicine. Their recent moves signal a shift in how ... |
| 01.04.2025 | Hims & Hers shares rise as company adds new weight-loss medications to platform | Hims & Hers Health is adding Eli Lilly's weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic injection liraglutide, to its platform.
The company's GLP-1 offerings have evolved as the company has contended ... |
| 30.03.2025 | Eggs are now the 2nd most expensive source of protein. Here are 6 more affordable options | LADO // Shutterstock
The Recommended Dietary Allowance for protein is 0.8 grams of protein per kilogram of body weight, or 0.36 grams per pound, though your intake amount might vary depending on whether you’re looking to lose weight, gain m... |
| 27.03.2025 | Novo Nordisk says copycat compounders are hurting Wegovy sales, may take legal action | Obesity drug giant Novo Nordisk said Thursday that the rampant growth of the U.S.’s compounded drug industry was hurting Wegovy sales.
CEO Lars Fruergaard Jørgensen told shareholders at its Annual General Meeting that it was pursuing legal ... |
| 13.03.2025 | Define Ventures: Carolyn Magill Named As Venture Partner | Define Ventures, which is one of the largest venture capital firms focused on early-stage health tech companies, announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, utilizing her 25 years of ... |
| 08.03.2025 | Hims & Hers to shut down dermatology business Apostrophe | Hims & Hers to shut down dermatology business Apostrophe
By ReutersMarch 7, 202511:23 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
The New York Stock Exchange with a Hims & Hers Healt... |
| 03.03.2025 | 40+ Exclusive Deals for Students, Teachers, and Healthcare Workers in 2025 | SheerID partners with leading brands to deliver year-round, exclusive offers to those who make a difference in our communities.
PORTLAND, Ore., March 03, 2025 (GLOBE NEWSWIRE) -- SheerID, the leading provider for verifying and engaging high... |
| 28.02.2025 | Navigating the Home Improvement Market: A Tale of Two Retail Giants | The home improvement sector is a battleground. Two titans, Home Depot and Lowe’s, are vying for supremacy amid shifting economic tides. As the market grapples with high interest rates and a sluggish housing market, both companies are adapti... |
| 28.02.2025 | Hims & Hers Faces a Storm: Shares Plummet Amid Weight Loss Business Concerns | Hims & Hers Health, a rising star in the telehealth sector, recently found itself in turbulent waters. The company’s shares took a nosedive, dropping 22% in a single day. This dramatic fall followed the release of its fourth-quarter res... |
| 25.02.2025 | Hims & Hers shares plunge 22% on concerns over weight loss business, margins | Hims & Hers shares fell on Tuesday, a day after the company released fourth-quarter results that disappointed on gross margin and outlined changes to its weight loss business.
The company reported $481 million in revenue for the quarter... |
| 25.02.2025 | 5 things to know before the stock market opens Tuesday | Stock futures were little changed after the market failed to stage a rebound Monday.
President Donald Trump indicated tariffs on Canada and Mexico could go into effect next week.
Home Depot narrowly beat Wall Street’s fourth-quarter earning... |
| 24.02.2025 | Hims & Hers shares tumble after company misses on margin, says may stop selling some weight loss drugs | Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended trading.
Revenue increased 95% from a year earlier to $481 million during the period.
In May, Hims & Hers ... |
| 24.02.2025 | Stocks making the biggest moves after hours: Hims & Hers Health, Tempus AI, Diamondback Energy and more | - |
| 22.02.2025 |
Cramer’s week ahead: Earnings from Nvidia, Dell and Home Depot | Monday - Friday, 6:00 - 7:00 PM ET
CNBC’s Jim Cramer walked investors through next week on Wall Street and highlighted earnings reports from Home Depot as well as tech giants Nvidia and Dell.
He also discussed the market’s decline over the ... |
| 21.02.2025 | Shares of Hims & Hers tumble 26% after FDA says semaglutide is no longer in shortage | The FDA said the shortage of semaglutide injection products such as Novo Nordisk’s Ozempic and Wegovy has been resolved.
The agency said it will start taking action against compounders, which are allowed to produce custom-made alternatives ... |
| 21.02.2025 | Shortage of Novo Nordisk’s Wegovy and Ozempic drugs is resolved, FDA says | The long-running U.S. shortage of Novo Nordisk’s blockbuster weight loss injection Wegovy and diabetes treatment Ozempic is resolved after more than two years, the Food and Drug Administration said.
The FDA’s decision will threaten the abil... |
| 21.02.2025 | Stocks making the biggest moves midday: UnitedHealth, Alibaba, Hims & Hers Health, Celsius and more | - |
| 18.02.2025 | Hims & Hers Earnings Could Be a Game Changer—What to Do Now After a massive 500% run over the past 12 months, shares of Hims & Hers stock might have another trick saved up before earnings ... |
There are a few stocks that come along every once in a while, arriving to change the way an old-fashioned industry works and operates. When investors get lucky enough to find one of them, it can typically bring on life-changing returns, ev... |
| 17.02.2025 | The Rise of naturalX Health Ventures: A New Era in Consumer Health Investment | In the bustling world of venture capital, a new player has emerged, ready to shake up the European healthcare landscape. naturalX Health Ventures has officially launched with a hefty €100 million fund, aiming to redefine consumer health. Th... |
| 17.02.2025 | €100 million for VC naturalX Health Ventures to fuel consumer health in Europe | Today, Berlin-based VC naturalX Health Ventures announced a €100 million fund to accelerate Healthcare in Europe, reportedly becoming the first specialised fund focused exclusively on the intersection of consumer and health in the European ... |
| 10.02.2025 | Super Bowl commercials rely on comedy and nostalgia to avoid potential missteps | Actor Glenn Powell did a take on Goldilocks for Ram Trucks, while comedian Nate Bargatze cloned himself and hired an opera singer because he saved so much money using DoorDash. Shaboozey took a lighthearted stroll through New Orleans for Ne... |
| 06.02.2025 | The Shifting Sands of Diversity Initiatives in Corporate America | In a surprising turn, Google has decided to scrap its diversity-based hiring targets. This move echoes a broader trend among U.S. corporations, which are reevaluating their diversity, equity, and inclusion (DEI) initiatives. Once a beacon o... |
| 06.02.2025 | The Shifting Sands of Diversity in Corporate America | In a landscape once dominated by promises of inclusivity, corporate America is witnessing a seismic shift. Google, a titan of the tech world, has decided to abandon its diversity-based hiring targets. This move echoes a broader trend among ... |
| 05.02.2025 | Aliens, sloths and silliness: Super Bowl ads offer laughs, celebs and surprises to win over viewers | With 80-plus ad spots divvied up among the 50-something advertisers during the game, it’s tough to make sure viewers remember your brand message. And with a few ad spots going for a record $8 million for 30 seconds this year, the stakes hav... |
| 20.01.2025 | Hims & Hers Health: A Stock to Trade or Own? HIMS achieved remarkable growth in 2024 but now faces challenges in 2025, raising the question of whether it suits traders better than long-term in... |
Hims & Hers Health Inc. (NYSE: HIMS), a telehealth company with a $6.1 billion valuation, has been a remarkable growth story, especially over the past year. The stock climbed an astounding 215% in 2024, significantly outperforming the ... |
| 10.12.2024 | Amazon’s Healthcare Gamble: A New Era of Medical Disruption Amazon's strategic healthcare expansion leverages technology and logistics for a potentially transformative impact on patient care and marke... |
Amazon (NASDAQ: AMZN) has recently started exploring more opportunities in the healthcare sector. This significant strategic shift for the e-commerce giant has the potential to reshape the industry and significantly impact Amazon’s financi... |
| 05.12.2024 | 3 Digital Health Companies Enhancing Patient Engagement The digital health industry has experienced impressive growth, driven by rising healthcare demands, digitalization, and technological innovation... | The digital health industry has experienced impressive growth, driven by rising healthcare demands, digitalization, and technological innovations. Amid this, Hims & Hers Health (HIMS), GoodRx Holdings (GDRX), and Talkspace (TALK) are st... |
| 20.09.2024 | The Digital Convergence: Sinch Email Camp and VK Board Innovations | In the fast-paced world of digital communication, two events stand out: Sinch's Email Camp and VK's Board updates. Both aim to enhance user experience and streamline workflows. These developments are not just incremental; they represent a s... |
| 20.09.2024 | The Illusion of Import Substitution: A Reality Check | In the realm of technology, the concept of import substitution often dances on the edge of optimism and reality. It’s a bit like building a house of cards; one wrong move, and the whole structure collapses. The recent discussions surroundin... |
| 18.09.2024 | Sinch Email Camp Returns: Get Ready for MessageMania | Join Industry Leaders & Channel Experts for a Fun, High-Quality Omnichannel Education Experience
ATLANTA, Sept. 18, 2024 /PRNewswire/ -- Sinch Sinch AB (publ) – (XSTO: SINCH), which is pioneering the way the world communicates through i... |
| 11.08.2024 | Haus: Decision Science Platform Company Raises $20 Million | Haus has announced $20 million in additional financing led by 01 Advisors (an investor group helmed by former Facebook CRO David Fischer) former Twitter CEO Dick Costolo, and former Twitter COO Adam Bain). Rahul Mehta, co-founder and managi... |
| 31.07.2024 | Haus secures additional financing from 01 Advisors; new product unveiled | Marketing measurement is an age-old problem: How does a brand know what’s working?, Haus is announcing $20M in additional financing led by 01 Advisors, an investor group helmed by former Facebook CRO David Fischer, former Twitter CEO Dick C... |
| 22.05.2024 | Health | Hims & Hers to sell inexpensive Ozempic alternative | Regulators recommended in January that pharmaceutical customers “should not use a compounded drug if an approved drug is available to treat a patient.”
Hims & Hers CEO Andrew Dudum told CNBC the company is working with one of the nation... |
| 20.05.2024 | Hims & Hers says it's selling a GLP-1 weight loss drug for 85% less than Wegovy. Here's the price. | Direct-to-consumer pharmaceutical startup Hims & Hers Health said it is selling injectable GLP-1 weight loss drugs for a fraction of the cost of brand-name competitors such as Wegovy and Ozempic. Following the announcement, shares of th... |
| 11.01.2024 | Hims & Hers Now Offers In-Person Care in Connecticut with Hartford HealthCare Partnership | What You Should Know:
Hims & Hers Health, Inc., the leading health and wellness platform, and Connecticut’s most transformative health system, Hartford HealthCare (HHC), today announced a strategic partnership that broadens access to in... |
| 06.11.2023 | Hims & Hers Launches AI Service to Help Providers Personalize Treatments | What You Should Know:
– Hims & Hers Health, the leading health and wellness platform, has unveiled MedMatch, an AI-powered solution designed to revolutionize healthcare by providing providers with a more intelligent and informed way to ... |
| - | Hims & Hers to offer at-home blood draws and lab testing with new acquisition | Hims and Hers Health has acquired at-home lab testing facility Trybe Labs.
The acquisition will allow the telehealth company to provide at-home lab testing through its platform.
The deal was completed through cash on hand and is expected to... |
